Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
June 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
June 22, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
June 21, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
June 13, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback Announce New Data For Investigational LAGEVRIO™ (molnupiravir) From Phase 3 MOVe-OUT Study
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Investor Event to Highlight Oncology Portfolio and Pipeline
June 07, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Adjuvant Treatment With Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Statistically Significant & Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
June 05, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Third-Quarter 2022 Dividend
May 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence
May 24, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
May 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
May 10, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in Bank of America Securities 2022 Healthcare Conference
May 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
April 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
April 29, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces First-Quarter 2022 Financial Results
April 28, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
April 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022
April 20, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
April 14, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28
April 08, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
April 05, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
April 04, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
April 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
April 01, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of Cancer
March 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
March 25, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer
March 23, 2022
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.